Leap Therapeutics Files 2024 10-K
Ticker: CYPH · Form: 10-K · Filed: Mar 26, 2025 · CIK: 1509745
| Field | Detail |
|---|---|
| Company | Leap Therapeutics, INC. (CYPH) |
| Form Type | 10-K |
| Filed Date | Mar 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
Leap Therapeutics filed its 2024 10-K. Financials and biz ops detailed.
AI Summary
Leap Therapeutics, Inc. filed its 2024 10-K on March 26, 2025, reporting financial results for the fiscal year ending December 31, 2024. The company, incorporated in Delaware, is based in Cambridge, MA, and operates in the pharmaceutical preparations sector. Key financial figures and details about its business operations and strategic developments are outlined in the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Leap Therapeutics' financial health and operational performance for the past fiscal year, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Leap Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 25,565,414 — Revenue (Reported for the fiscal year ending 2024-12-31.)
- 38,329,894 — Net Income/Loss (Reported for the fiscal year ending 2024-12-31.)
- 420,000 — Operating Expenses (Reported for the fiscal year ending 2024-12-31.)
Key Players & Entities
- LEAP THERAPEUTICS, INC. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-03-26 (date) — Filing Date
- Cambridge, MA (location) — Business Address
- 2834 (industry_code) — Standard Industrial Classification
- Flame Biosciences, Inc. (company) — Acquisition/Related Entity
FAQ
What were Leap Therapeutics' total revenues for the fiscal year ended December 31, 2024?
Leap Therapeutics reported total revenues of $25,565,414 for the fiscal year ended December 31, 2024.
What was the company's net income or loss for the fiscal year ended December 31, 2024?
The company reported a net income/loss of $38,329,894 for the fiscal year ended December 31, 2024.
When did Leap Therapeutics file its 10-K for the fiscal year 2024?
Leap Therapeutics filed its 10-K for the fiscal year 2024 on March 26, 2025.
What is Leap Therapeutics' Standard Industrial Classification code?
Leap Therapeutics' Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What significant events or related entities are mentioned in the filing context?
The filing mentions entities such as Flame Biosciences, Inc. and various warrant and preferred stock series, indicating potential acquisitions, financings, or strategic partnerships.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 26, 2025 regarding LEAP THERAPEUTICS, INC. (CYPH).